TY - JOUR
T1 - Oral Pharmacologic Management of Overactive Bladder Syndrome
T2 - Where Do We Stand?
AU - Marcelissen, Tom
AU - Rashid, Tina
AU - Lopes, Tiago Antunes
AU - Delongchamps, Nicolas Barry
AU - Geavlete, Bogdan
AU - Rieken, Malte
AU - Cornu, Jean-Nicolas
AU - Rahnama'i, Mohammad Sajjad
AU - EAU Young Academic Urologists (YAU) Functional Urology Working Group
N1 - Funding Information:
Various antimuscarinic drugs are currently available in the treatment of OAB. The introduction of mirabegron has broadened the therapeutic approach, and combination therapy of both agents can be valuable in clinical practice. However, patient adherence to most drugs for OAB is still relatively poor. Healthcare providers need to identify and utilize strategies to improve treatment adherence by defining clear treatment goals, implement educational methods, and frequently communicate with patients to identify problems with adherence. In elderly patients, anticholinergics should be prescribed with care, and adequate knowledge regarding pharmacokinetics and drug interactions in essential. Also, patient expectations should be clearly discussed. The management of OAB should be patient-centered and tailored to their individual needs and expectations. Author contributions: M.S. Rahnama'i had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Marcelissen , Cornu. Acquisition of data: Marcelissen , Cornu, Rashid, Geavlete. Analysis and interpretation of data: Marcelissen , Cornu, Rashid, Geavlete, Antunes Lopes. Drafting of the manuscript: Marcelissen , Cornu, Rashid, Geavlete, Antunes Lopes, Rahnama'i, Delongchamps Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: None. Obtaining funding: None. Administrative, technical, or material support: Rahnama'i Supervision: None. Other: None. Financial disclosures: M.S. Rahnama'i certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Funding/Support and role of the sponsor: None.
Publisher Copyright:
© 2018 European Association of Urology
PY - 2019/11
Y1 - 2019/11
N2 - Overactive bladder syndrome (OAB) is a prevalent disorder with a significant impact on quality of life. Despite this high prevalence, there is significant underdiagnosis and undertreatment due to several barriers, including embarrassment, poor communication and low patient adherence.Currently, various antimuscarinic are available in the treatment of OAB. The introduction of mirabegron has broadened the therapeutic approach and combination therapy of both agents can be valuable in clinical practice. Yet, patient adherence to most drugs for OAB is still relatively poor. Healthcare providers need to identify and utilise strategies to improve treatment adherence by defining clear treatment goals, implement educational methods and frequently communicate with patients to identify problems with adherence. The elderly population form need special attention as in these patients, anticholinergics should be prescribed with care and adequate knowledge regarding pharmacokinetics and drug interactions in essential. Furthermore, patient expectations should be clearly discussed.In this narrative review, the current advances in oral pharmacotherapy are evaluated and the most important factors involved in the management of OAB are discussed. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
AB - Overactive bladder syndrome (OAB) is a prevalent disorder with a significant impact on quality of life. Despite this high prevalence, there is significant underdiagnosis and undertreatment due to several barriers, including embarrassment, poor communication and low patient adherence.Currently, various antimuscarinic are available in the treatment of OAB. The introduction of mirabegron has broadened the therapeutic approach and combination therapy of both agents can be valuable in clinical practice. Yet, patient adherence to most drugs for OAB is still relatively poor. Healthcare providers need to identify and utilise strategies to improve treatment adherence by defining clear treatment goals, implement educational methods and frequently communicate with patients to identify problems with adherence. The elderly population form need special attention as in these patients, anticholinergics should be prescribed with care and adequate knowledge regarding pharmacokinetics and drug interactions in essential. Furthermore, patient expectations should be clearly discussed.In this narrative review, the current advances in oral pharmacotherapy are evaluated and the most important factors involved in the management of OAB are discussed. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
KW - Drug
KW - Incontinence
KW - Medication
KW - Overactive bladder syndrome
KW - Pharmacology
KW - Urgency
KW - DOUBLE-BLIND
KW - ANTIMUSCARINIC AGENTS
KW - COGNITIVE FUNCTION
KW - ANTICHOLINERGIC PROPERTIES
KW - MIRABEGRON
KW - EFFICACY
KW - SOLIFENACIN
KW - ADHERENCE
KW - PERSISTENCE
KW - THERAPY
U2 - 10.1016/j.euf.2018.03.011
DO - 10.1016/j.euf.2018.03.011
M3 - (Systematic) Review article
C2 - 29625926
SN - 2405-4569
VL - 5
SP - 1112
EP - 1119
JO - European Urology Focus
JF - European Urology Focus
IS - 6
ER -